On August 29, Fosun Pharma received another RMB 300 million financial support for 5 years (about $47 million) from International Finance Corporation (IFC), a member of World Bank Group, which will help Fosun Pharma to further expand the business scale and speed up the process of internationalization.

Fosun Pharma is a leading listed company in Chinese pharmaceutical industry, which therapeutic areas has covered the following aspects as alimentary canal, metabolism, cardiovascular system, anti-infective, anti-cancer and nerve system and so on. Fosun Pharma has attained the domestic leading competitive advantage for hepatic disease, diabetes, antimalarials, tuberculosis and other indications in segment market.

Through the cooperation with the international institutions such as World Health Organization and International Red Cross and so on, Fosun Pharma is also one of the main suppliers of antimalarial drugs to the developing countries, up to now, it has provided Artesunate series antimalarial drugs for more than 300 million people to the Africa and southeast Asia, and saved nearly one hundred million people's lives.

“IFC’s support plays an important role in the previous development of Fosun Pharma, in the future, we will further develop the overseas market, and strive to become China's first-class pharmaceutical enterprise with international competitiveness”, Chen QiYu, Chairman of Fosun Pharma said. “The current market environment is full of challenges, the internationalization industry concept and long-term stable financial support from IFC enable us to consolidate and expand our pharmaceutical business.”

IFC’s loan will provide the long-term funding for Fosun Pharma’s Chinese subsidiaries, including those in the less developed areas, to help Fosun Pharma upgrades the existing facilities and further enhance the effectiveness of products.

“We are keen to provide financing to key Chinese private sector clients that create thousands of jobs as they grow and cater to the needs of underserved populations,” said IFC’s Director for East Asia and the Pacific Sérgio Pimenta. “By supporting companies like Fosun Pharma, we are helping ensure that the benefits of economic growth reach the poor.”

In 2006, IFC provided RMB 320 million to Fosun Pharma through the issuance of RMB bonds (namely the panda bonds), which helped the enterprise to expand its production scale and distribution channel. Meanwhile, Fosun Pharma increased the investment in the Artesunate industry with IFC’s support. So far, the number of the antimalarial drugs of Fosun Pharma’s Guilin pharma passed the PQ Certification of World Health Organization has reached 5 (including Artesunate tablets, Amodiaquine tablets, combination of Artesunate tablets+ Amodiaquine tablets, Artesunate for injection, combination of Artesunate tablets+ Sulfadoxine/Pyrimethamine tablets), and it continued to play the leading role in the field of antimalarial.

The new loan will be funded through IFC’s landmark Renminbi Swap Facility with Chinese banks. IFC uses the RMB swap project to release RMB loans, so as to provide foreign capital with a low cost and help Fosun Pharma to avoid foreign-exchange risks. IFC is the first multilateral institution authorized to conduct transactions with Chinese banks in the domestic currency swap market.

About Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998, now it has turned a leading listed company in Chinese pharmaceutical industry. Fosun Pharma specializes in modern biological medical & health industry, seize great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and strategically covered the important links of medical & health industry in R&D, manufacturing, distribution and terminals, and has implemented core competiveness strategy in the respect of R&D, innovation, marketing, merging & integration and team building, and has become a large professional pharmaceutical group regarding pharmaceutical manufacturing as the core and taking the lead of the scale and market role in pharmaceutical commerce, diagnostic medicines, medical service and medical instruments. Fosun Pharma’s net profit has increased by 21 times since its 14-year listed and its annual compound growth rate has reached 26.72%. Meanwhile, its sales, net asset, net profit and the market value of stocks are in front rank of the listed companies in Chinese pharmaceutical industry. For more information please visit the following website: www.fosunpharma.com

About IFC (International Finance Corporation)

IFC, a member of the World Bank Group, is the largest global development institution focused exclusively on the private sector. We help developing countries achieve sustainable growth by financing investment, mobilizing capital in international financial markets, and providing advisory services to businesses and governments. In FY12, our investments reached an all-time high of more than $20 billion, leveraging the power of the private sector to create jobs, spark innovation, and tackle the world’s most pressing development challenges. For more information, visit www.ifc.org.